+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.

Age: 18Years - 80YearsAll GendersPhase 2
56 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.

Age: 18Years +All GendersPhase 3
183 locations
R

Actively Recruiting

Researchers are investigating treatments for participants with unresectable stage III Non-small Cell Lung Cancer NSCLC who have completed platinum-based concurrent chemoradiation therapy without disease progression. This Phase 3 randomized study compares the effects of two drugs, Pumitamig and Durvalumab, to evaluate their impact on progression-free survival and other clinical outcomes over several years. The trial is sponsored by Bristol-Myers Squibb and aims to better understand treatment options after initial chemoradiation. Participants are randomly assigned to receive either Pumitamig or Durvalumab monotherapy, each given at specified doses on specified days. The study treatment follows completion of concurrent chemoradiotherapy, with no masking or placebo involved. The trial includes an observation period lasting up to three years for primary outcome measures and extends up to approximately nine years for overall survival monitoring. During the study, participants will undergo regular assessments to monitor progression-free survival based on standardized imaging criteria, along with evaluations of overall survival, response rates, disease control, and treatment duration. These assessments are conducted by blinded independent reviewers and investigators. Participants will be monitored closely for safety and treatment effects throughout the trial, which spans several years from enrollment through long-term follow-up.

Age: 18Years +All GendersPhase 3
260 locations
I

Actively Recruiting

Researchers are conducting an international, multicenter, open-label phase III trial to evaluate the addition of adjuvant durvalumab after neoadjuvant chemotherapy combined with durvalumab and surgery in patients with early-stage, operable non-small cell lung cancer NSCLC stages IIB to IIIB. The main goal is to see if giving durvalumab after surgery improves disease-free survival in patients who do not achieve complete pathological response after initial treatment. The treatment plan involves 3 to 4 cycles of neoadjuvant durvalumab combined with platinum-based doublet chemotherapy, followed by surgery to remove the tumor. After surgery, patients with complete R0 or microscopic residual R1 resection are randomly assigned to either receive adjuvant durvalumab given intravenously at 1500 mg every 4 weeks for up to 12 cycles or to be observed without additional treatment. Participants will be monitored regularly for about 60 months after randomization to assess disease-free survival and other outcomes such as overall survival, time to recurrence, and treatment toxicity. Assessments include imaging scans to check for metastatic disease, pathological review after surgery, and ongoing safety evaluations. Participants must attend scheduled visits and follow study procedures throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
42 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.

Age: 18Years +All GendersPhase 3
210 locations
F

Actively Recruiting

Researchers are conducting the FLUDRO-SHOCK trial to find better treatments for adults with septic shock, a serious condition caused by severe infection. This phase 3 international trial compares two doses of the steroid fludrocortisone 50 mcg and 100 mcg against a placebo, alongside the usual hydrocortisone treatment. The study also investigates how a persons gene-based immune response may influence treatment effects. Up to 2,200 critically ill patients in intensive care units across multiple countries are expected to participate. Participants will receive either 50 mcg or 100 mcg of fludrocortisone acetate daily, or a matching placebo tablet, given orally or through a gastric tube for 7 days or until discharge from intensive care, whichever comes first. The study uses a randomized, double-blind design to fairly compare these treatments. Researchers will closely monitor patients during this treatment period. Throughout the study, participants survival, organ support needs, and quality of life will be tracked for up to one year after enrollment. Assessments include the number of days alive without organ support, mortality at multiple time points, new kidney therapy needs, mechanical ventilation days, hospital readmissions, new infections, and functional and health-related quality of life questionnaires. This comprehensive monitoring aims to help identify the most effective and personalized steroid treatment approach for septic shock.

Age: 18Years +All GendersPhase 3
8 locations
R

Actively Recruiting

This research aims to evaluate whether early use of enteral fludrocortisone can reduce death and dependency six months after aneurysmal subarachnoid haemorrhage aSAH, a severe type of stroke that mainly affects adults aged 45 to 64 and more often women. The condition has a high mortality rate and many survivors face lasting neurological and cognitive problems, impacting their quality of life and ability to work. The study will address the need for better treatment options given the high healthcare costs and poor outcomes associated with aSAH. Participants will be randomly assigned to receive either fludrocortisone or a matched placebo tablet every six hours by mouth for 14 days. Fludrocortisone is a synthetic steroid that helps retain sodium and fluids, potentially preventing hyponatraemia, a common and serious complication of aSAH that can worsen brain swelling and increase the risk of further brain injury. This trial is blinded and controlled to compare the effects of fludrocortisone against placebo in critically ill patients. During the study, participants will be monitored in a critical care setting with regular assessments including neurological evaluations and laboratory tests. The main outcome measured will be the level of disability or recovery at six months using the Modified Rankin Scale. Additional assessments will include quality of life tools specific to subarachnoid haemorrhage. Safety and side effects will be closely observed throughout the study. The total duration of participation includes treatment and follow-up assessments up to six months after randomization.

Age: 18Years +All GendersPhase 2
16 locations
E

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the safety and efficacy of STL303 capsules in patients diagnosed with primary Immunoglobulin A nephropathy IgAN. The trial seeks to determine the optimal clinical dose of STL303 while monitoring its effects closely in this patient population. Participants who are already receiving background therapy will be randomly assigned in equal groups to receive one of two different doses of STL303 or a placebo. These capsules are taken orally once daily. The study includes several dosing cohorts and placebo controls to compare the outcomes across groups. Throughout the trial, participants will attend multiple clinic visits for safety monitoring, including reporting adverse events on Days 7, 14, 30, 45, 60, 90, 135, 180, and a safety follow-up on Day 210. The study also involves various assessments such as urine and blood tests to measure protein levels, kidney function, and drug concentration at specified intervals. This detailed monitoring will help researchers understand the drugs impact and safety over the treatment period.

Age: 18Years +All GendersPhase 2
8 locations

1-10 of 11

1